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Abstract
Background: Cancer and inflammation are associated with cachexia. Withania somnifera (W. somnifera) possesses
antioxidant and anti-inflammatory potential. We investigated the potential of an aqueous extract of the root of W.
somnifera (WRE) to modulate cytokines, antioxidants and apoptosis in leukaemic THP-1 cells and peripheral blood
mononuclear cells (PBMC’s).
Methods: Cytotoxcity of WRE was determined at 24 and 72 h (h). Oxidant scavenging activity of WRE was evaluated
(2, 2-diphenyl-1 picrylhydrazyl assay). Glutathione (GSH) levels, caspase (− 8, − 9, − 3/7) activities and adenosine
triphosphate (ATP) levels (Luminometry) were thereafter assayed. Tumour necrosis factor-α (TNF-α), interleukin (IL)-6,
IL-1β and IL-10 levels were also assessed using enzyme-linked immunosorbant assay.
Results: At 24 h, WRE (0.2–0.4 mg/ml) decreased PBMC viability between 20 and 25%, whereas it increased THP-1
viability between 15 and 23% (p < 0.001). At 72 h, WRE increased PBMC viability by 27–39% (0.05, 0.4 mg/ml WRE)
whereas decreased THP-1 viability between 9 and 16% (0.05–0.4 mg/ml WRE) (p < 0.001). Oxidant scavenging activity was
increased by WRE (0.05–0.4 mg/ml, p < 0.0001). PBMC TNF-α and IL-10 levels were decreased by 0.2–0.4 mg/ml WRE,
whereas IL-1β levels were increased by 0.05–0.4 mg/ml WRE (p < 0.0001). In THP-1 cells, WRE (0.05–0.4 mg/ml) decreased
TNF-α, IL-1β and IL-6 levels (p < 0.0001). At 24 h, GSH levels were decreased in PBMC’s, whilst increased in THP-1 cells by
0.2–0.4 mg/ml WRE (p < 0.0001). At 72 h, WRE (0.1–0.4 mg/ml) decreased GSH levels in both cell lines (p< 0.0001). At 24 h,
WRE (0.2–0.4 mg/ml) increased PBMC caspase (-8, -3/7) activities whereas WRE (0.05, 0.1, 0.4 mg/ml) increased THP-1
caspase (-9, -3/7) activities (p < 0.0001). At 72 h, PBMC caspase (-8, -9, -3/7) activities were increased at 0.05–0.1 mg/ml WRE
(p < 0.0001). In THP-1 cells, caspase (-8, -9, -3/7) activities and ATP levels were increased by 0.1–0.2 mg/ml WRE, whereas
decreased by 0.05 and 0.4 mg/ml WRE (72 h, p < 0.0001).
Conclusion: In PBMC’s and THP-1 cells, WRE proved to effectively modulate antioxidant activity, inflammatory cytokines
and cell death. In THP-1 cells, WRE decreased pro-inflammatory cytokine levels, which may alleviate cancer cachexia and
excessive leukaemic cell growth.
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Background
Chronic inflammation plays an essential role in malignan-
cies [1] through the initiation, promotion and progression
of tumours [2]. Usually, the host-mediated anti-tumour ac-
tivity overcomes the tumour-mediated immunosuppressive
activity leading to the elimination of cancerous cells [2].
However, in the presence of an inadequate host anti-
tumour defence, the pro-inflammatory tumour microenvir-
onment is enhanced and promotes tumour development,
invasion, angiogenesis and metastasis [2].
The cachectic syndrome is prominent in malignancies
occurring in up to 50% of all cancer patients [3]. It is a
progressive, debilitating condition leading to abnormal
weight loss, as a result of adipose tissue (85%) and skeletal
muscle (75%) depletion [3–5]. Modulation of lipogenesis
and lipolysis is essential in maintaining adipose tissue mass.
Lipoprotein lipase (LPL) hydrolyses fatty acids (FA’s) from
plasma lipoproteins, thereafter FA’s are transported to adi-
pose tissue for triacylglycerol (TAG) production, whereas
hormone sensitive lipase (HSL) hydrolyses TAG’s into FA’s
and glycerol [3]. Literature shows that decreased serum
LPL levels/activity and increased HSL levels/activity are as-
sociated with cachexia [6–8]. Additionally, increased prote-
olysis [9] and decreased proteogenesis has been established
in cachectic patients [10]. The ATP-ubiquitin-dependent
proteolytic pathway has been shown to be responsible for
the accelerated proteolysis seen in a variety of wasting con-
ditions, including cancer cachexia [11].
Inflammatory cytokines, oxidative stress and apoptosis
have been implicated in the initiation and progression of
cancer, imbalance of catabolic/anabolic processes [12]
and development of cachexia [13]. Production of inflam-
matory cytokines [tumour necrosis factor-α (TNF-α),
interleukin (IL) – 6, and IL-1β] is activated by lipopoly-
saccharide (LPS) that potently stimulates macrophages
[14, 15]. The LPS signal is transduced by LPS binding to
LPS binding protein, delivered to CD14 and transferred
to Toll like receptor-4 [16]. Nuclear factor kappa B (NF-
κB) is subsequently activated and regulates the transcrip-
tion of genes associated with inflammation, proliferation,
invasion, angiogenesis and apoptosis [1, 17–19]. Pro-
inflammatory cytokines (TNF-α, IL-6 and IL-1) have
been shown to decrease LPL activity [20–23], which re-
duces the uptake of exogenous lipids by adipose tissue
[21], ultimately decreasing lipogenesis. Additionally, pre-
vious studies have indicated that TNF-α increased ubi-
quitin (concentrations and mRNA), while IL-6 increased
the 26S proteasome and cathepsins activities, which may
activate proteolytic pathways [4, 24–26], ultimately in-
creasing proteolysis. In combination, excessive levels of
pro-inflammatory cytokines increase tumour suppressive
activity [2] and tissue wasting [3].
Reactive oxygen species (ROS) have been associated
with tumour initiation, inflammation [2, 27] and muscle
wasting [28]. However, antioxidants have been shown to
decrease muscle wasting by neutralizing ROS [1, 28]. Ele-
vated ROS levels activate apoptotic pathways, ultimately
activating caspase-3 [29]. Caspase-3 activation plays
an essential role in the execution of apoptosis, as well
as muscle proteolysis [30]. In addition, in weight los-
ing upper gastro-intestinal tract cancer patients, deoxyribo-
nucleic acid (DNA) fragmentation and poly (ADP-ribose)
polymerase (PARP) cleavage were increased, whereas
MyoD protein was decreased, indicating increased apop-
tosis and decreased muscle replenishment [3].
Cancer patients suffer from a wide range of side-effects
caused by current cancer chemotherapeutic and radiothera-
peutic agents. Patients are constantly seeking alternative
traditional remedies to alleviate their discomfort. Withania
somnifera (L.) Dunal (W. somnifera) is a well known medi-
cinal plant cultivated in India, parts of East Asia and Africa
[31]. It is commonly referred to as Ashwagandha and
belongs to the Solanaceae family [31]. Compounds isolated
from W. somnifera include withaferin A and 3-β-hydroxy-
2, 3 dihydro withanolide F [32]. The major constituent of
the root extract of W. somnifera is withanolide-A [33]. W.
somnifera is frequently used in Ayurvedic medicine due to
its various medicinal properties [31]. These properties in-
clude anti-inflammatory [34], antioxidant and immune-
modulatory activities [35]. W. somnifera was found to be an
immune regulator in inflammation animal models [36].
The immunosuppressive action of W. somnifera may be
due to the presence of withanolides, steroidal lactones and
a few flavanoids [37]. In addition, W. somnifera formulation
(WSF) has shown anti-proliferative potential in human
promyelocytic leukemia (HL-60) cells, by activating the
intrinsic and extrinsic apoptotic pathways [38]. When
used together, W. somnifera formulations aid the host
to effectively fight cancer and reduce the harmful ef-
fects of chemotherapy and radiotherapy [39].
There is a need for the discovery of an inexpensive
cancer cachectic treatment to improve the prognosis of
cancer patients and to establish a mechanism of regulation
of the immune system, inflammasome and apoptosis in
order to prevent/decelerate the rapid depletion of skeletal
muscle and adipose tissue. We investigated the effect of
an aqueous extract of the root of W. somnifera (WRE) on
antioxidant capacity, inflammatory cytokine levels and cell
death induction in leukaemic THP-1 cells and peripheral
blood mononuclear cells (PBMC’s).
Methods
Materials
The roots of W. somnifera were collected on the 11th of
March 2011 (collectors number: Immelman 427) from the
Eastern Cape [the Ntubeni Location near Dwesa Reserve],
South Africa (SA) and identified by Dr. Kathleen Immelman
from the Department of Botany at the Walter Sisulu
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University, SA and further comparison to South African
data [40]. Voucher specimens were deposited at the KEI
herbarium (13995). THP-1 cells were obtained from from
American Type Culture Collection (ATCC, University
Boulevard Manassas, Virginia, USA). RPMI-1640 and BD
OptEIA enzyme-linked immunosorbant assay (ELISA)
cytokine kits were purchased from The Scientific Group
(Johannesburg, SA). Foetal calf serum (FCS) and Pen/
Strep Amphotericin B (PSF) were acquired from White-
head Scientific (Cape Town, SA). Dimethyl sulphoxide
(DMSO) was purchased from Merck (Johannesburg, SA).
Histopaque-1077, LPS and 2, 2-diphenyl-1 picrylhydrazyl
(DPPH) were purchased from Sigma (Aston Manor, SA).
The 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-
1,3-benzene disulphonate (WST-1) cell proliferation re-
agent was purchased from Roche (Johannesburg, SA).
Promega (Madison, USA) supplied the caspase (-3/7,
-8, -9), adenosine triphosphate (ATP) and glutathione
(GSH) kits.
Plant extraction
The roots of W. somnifera were dried and milled before
being sequentially extracted in ethanol and distilled water.
Ethanol (200–350 ml) was added to the milled root (10–
30 g) and extracted overnight by shaking (4×g, 37 °C). The
ethanol extracts were thereafter filtered, evaporated using
a rotary evaporator, dried (37 °C) and stored (4 °C). The
root material was thereafter extracted with distilled water
(200–350 ml) by shaking (4×g, 75 °C) for a period of
6 hours (h). Water extracts were filtered, dried and stored
(4 °C).
The 2, 2-diphenyl-1 picrylhydrazyl assay
WRE (0.05–0.4 mg/ml) and butylated hydroxytoluene
(BHT) (60–300 μM) dilutions were prepared in metha-
nol (99.5% and grade AR). A 50 μM DPPH solution was
prepared from a stock solution of 0.135 mM DPPH in
methanol. WRE, BHT dilutions and methanol (1 ml) were
aliquoted into 15 ml polypropylene tubes, followed by the
50 μM DPPH solution (1 ml). Reaction mixtures were
vortexed and incubated [room temperature (RT), 30 min
(min)] in the dark. Absorbance of samples was read at
517 nm using aVarine Cary 50 UV-visible spectrophotom-
eter (McKinley Scientific, New Jersey, US).
Isolation of peripheral blood mononuclear cells
Buffy coats containing PBMC’s were obtained from the
South African National Blood Service (2011/09). PBMC’s
were extracted by differential centrifugation. Buffy coats
(5 ml) were layered onto equivolume histopaque-1077
(5 ml) in 15 ml polypropylene tubes and centrifuged
(400×g, 21 °C for 30 min). After centrifugation, the PBMC’s
were transferred to sterile 15 ml polypropylene tubes, phos-
phate buffered saline (PBS) was added (0.1 M, 10 ml) and
tubes were centrifuged (400×g, 21 °C, 15 min). Cell density
of isolated PBMC’s was adjusted (1 × 106 cells/ml) using the
trypan blue exclusion test and cryo-preserved (10% FCS,
10% DMSO) using a NELGENE cryo freezing container
and stored at -80 °C.
Tissue culture
THP-1 cells were grown in the appropriate tissue culture
conditions in a 75 cm3 tissue culture flask (37 °C, 5%
CO2). The growth media comprised of RPMI-1640, FCS
(10%) and PSF (2%). Cells were thawed, seeded into a
75 cm3 tissue culture flask at a concentration of 3 × 105
cells/ml and incubated (37 °C, 5% CO2). THP-1 cells
were allowed to grow for 2–3 days before the cells were
centrifuged (162×g, 10 min) and re-suspended in fresh
growth media. The number of cells should not exceed
8 × 105 cells/ml, therefore the cells/ml was quantified daily
by trypan blue staining. Once the cell count reached
8 × 105 cells/ml the THP-1 cells were split/diluted to
3 × 105 cells/ml with media and incubated. Subsequent
experiments were conducted once the cell numbers
were sufficient.
Cell viability assay
Cytotoxicity of WRE in PBMC’s and THP-1 cells was mea-
sured using the WST-1 assay (Roche, Johannesburg, SA).
PBMC and THP-1 cells (10,000 cells/well, 96-well plate, in
triplicate wells) were stimulated with LPS (20 μg/ml, 37 °C,
5% CO2, 4 h) before exposure to WRE (0.05–0.4 mg/ml) for
24 and 72 h (37 °C, 5% CO2). Similarly, controls received
media. Thereafter, plates were centrifuged (162×g, 10 min),
supernatant removed, cell pellets re-suspended in growth
media (100 μl/well), WST-1 reagent (10 μl/well) added
and plates incubated (37 °C, 5%, CO2, 3 h). Optical density
was measured at 450 nm (620 nm reference wavelength)
with a BIO-TEK μQuant spectrophotometer (Analytical
and Diagnostic Products, SA). This experiment was con-
ducted independently on three occasions.
Stimulation and treatment of cells
PBMC’s and THP-1 cells (1 × 105 cells/ml) were transferred
into 24-well plates and stimulated with LPS (20 μg/ml,
37 °C, 5% CO2, 4 h) before exposure to WRE (0.05–0.
4 mg/ml) for 24 h (TNF-α) and 72 h (IL-1β, IL-6, IL-
10) (37 °C, 5% CO2). After incubation, plates were cen-
trifuged (162×g, 10 min) and the supernatant collected
and stored (− 80 °C) for cytokine analysis. Cell pellets
were used to conduct the caspase (-8, -9, -3/7) activity,
as well as ATP and GSH assays. The experiments were
conducted independently (twice) for all subsequent
assays.
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Quantification of cytokines
Cytokine levels were estimated using the BD OptEIA
ELISA kits (The Scientific Group, SA) and the procedure
was followed as per the instruction manual. ELISA plates
were coated with capture antibody overnight (100 μl/
well, 4 °C). Thereafter, plates were washed (3×) with
wash buffer and blocked with assay diluent (200 μl/well,
1 h, RT). Standard solutions were prepared by diluting a
stock solution [TNF-α, IL-10 (500 pg/ml), IL-6 (300 pg/ml)
, IL-1β (250 pg/ml)] serially [TNF-α, IL-10 (500–7.8 pg/ml),
IL-6 (300–4.7 pg/ml), IL-1β (250–3.9 pg/ml)]. Plates were
washed (3×), standards and samples (100 μl/well) were ali-
quoted into appropriate wells and plates were incubated
(2 h, RT). Plates were washed (5×), working detector
(100 μl/well) added and plates incubated (1 h, RT). The
plates were washed (7×), substrate solution (100 μl/well)
added and plates were incubated (30 min, RT) in the
dark. Finally, stop solution (50 μl/well) was added and
the absorbance was read at 450 nm (570 nm reference
wavelength) with a Multiskan FC micro-plate reader
(Thermo Scientific). Cytokine concentrations were
calculated by extrapolation from a standard curve.
The glutathione assay
The GSH-Glo™ assay (Promega, Madison, USA) was per-
formed to measure GSH levels. Standard GSH solutions
were prepared by diluting a 5 mM stock solution serially
(1.56–50 μM) and PBS (0.1 M) was the standard blank.
Cells (50 μl/well, 2 × 105 cells/ml) and standards were
added into an opaque 96-well plate, followed by GSH-
Glo™ reagent (25 μl/well) and allowed to incubate (30 min,
RT) in the dark. Luciferin detection reagent (50 μl/well)
was subsequently added and plates incubated (15 min,
RT) in the dark. The absorbance was read on a Modulus™
microplate luminometer (Turner Biosystems, Sunnyvale,
USA) and GSH concentrations were calculated by ex-
trapolation from a standard curve.
Caspase and ATP assays
Caspase activity and ATP levels were determined using the
Caspase-Glo®-3/7, -8, -9 and ATP assay kits (Promega,
Madison, USA). Caspase-Glo®-3/7, -8, -9 and ATP reagents
were reconstituted according to the manufacturer’s in-
structions. Cells (100 μl, 2 × 105 cells/ml) were added
into duplicate wells of a microtitre plate for each assay,
thereafter caspase -3/7, -8, -9 and ATP reagents (100 μl/
well) were added into appropriate wells. The plate was
incubated (30 min, RT) in the dark. Luminescence was
measured on a Modulus™ microplate luminometer (Turner
BioSystems) and expressed as relative light units (RLU).
Statistical analysis
Statistical analysis was performed using the STATA and
GraphPad Prism statistical analysis software. The one-
way analysis of variance (ANOVA) was used to compare
between groups, followed by the Tukey multiple compari-
sons test, with p < 0.05 defining statistical significance.
Results
The oxidant scavenging potential of WRE
The oxidant scavenging activity of WRE using the DPPH
assay is shown in Fig. 1. WRE (0.05–0.4 mg/ml) signifi-
cantly increased DPPH scavenging activity by 13.33–46.
38% (Fig. 1, p < 0.0001).
The in vitro cytotoxicity of WRE
The WST-1 assay was used to determine cell viability of
THP-1 cells and PBMC’s after treatment with WRE (Fig. 2).
At 24 h, WRE (0.05–0.4 mg/ml) decreased PBMC viability by
20.69–25.15% while WRE (0.2–0.4 mg/ml) increased THP-1
viability by 15.99–22.54% as compared to the controls
(Fig. 2a and c, p < 0.001). This result suggests that PBMC’s
are more sensitive to WRE treatment than THP-1 cells.
At 72 h, PBMC viability was increased (27.16–38.58%)
by WRE (0.05, 0.4 mg/ml), as compared to the control
(Fig. 2b, p < 0.0001). In the same time period, WRE (0.
05–0.4 mg/ml) decreased THP-1 viability by 9.07–16.
09% relative to the control (Fig. 2d, p=0.0002).
The immune suppressive properties of WRE
WRE altered cytokine levels in PBMC’s and THP-1 cells (Fig.
3 and Fig. 4). The levels of TNF-α, IL-1β, IL-6 and IL-10
produced by LPS stimulated PBMC’s was 336.218, 168.100,
657.878 and 46.990 pg/ml respectively. WRE (0.2–0.4 mg/
ml) decreased PBMC TNF-α and IL-10 levels as com-
pared to the control (Fig. 3a and d, p < 0.0001). In
PBMC’s, IL-6 levels were decreased by 0.4 mg/ml
WRE, whereas IL-1β levels were increased by 0.05–0.
4 mg/ml WRE relative to the control (Fig. 3b and c,
p < 0.0001).
Fig. 1 Percentage DPPH scavenging activity of WRE (Values expressed
as mean ± SD, * p < 0.05, *** p < 0.0001, compared to control)
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The levels of TNF-α, IL-1β, IL-6 and IL-10 produced by
LPS stimulated THP-1 cells were 13.285, 21.947, 78.622
and 2.705 pg/ml respectively. In THP-1 cells, TNF-α, IL-
1β and IL-6 levels were decreased by 0.05–0.4 mg/ml
WRE, whilst IL-10 levels were decreased by 0.4 mg/ml
WRE as compared to the control (Fig. 4, p < 0.003).
The antioxidant potential of WRE
The endogenous antioxidant activity of WRE was deter-
mined by measuring GSH levels in both cell lines
(Table 1). At 24 h, GSH levels in PBMC’s were decreased
by WRE (0.05, 0.2, 0.4 mg/ml) relative to the control
(Table 1, p < 0.0001). In THP-1 cells, GSH levels were
decreased at 0.05 mg/ml WRE whereas increased (0.41–
1.62 μM) at 0.1–0.4 mg/ml WRE compared to the con-
trol (Tables 1, 24 h, p < 0.0001).
At 72 h, PBMC GSH levels were increased at 0.05 mg/ml
whereas decreased 0.1–0.4 mg/ml WRE compared to the
control (Table 1, p < 0.0001). WRE (0.05–0.4 mg/ml) de-
creased GSH levels in THP-1 cells relative to the control
(Tables 1, 72 h p < 0.0001).
WRE modulates caspase (-8, -9, -3/7) activities and ATP
levels
Luminometry assays were used to determine caspase ac-
tivity and ATP levels in THP-1 cells and PBMC’s after
treatment with WRE. The pro-apoptotic effect of WRE in
PBMC’s treated for 24 h is shown in Table 2. At 24 h,
PBMC caspase-8 activity was decreased by 0.05 mg/ml
WRE whereas increased by 0.2–0.4 mg/ml WRE compared
to the control (Table 2, p < 0.0001). PBMC caspase-9
activity was increased by 0.05 and 0.2 mg/ml WRE but de-
creased by 0.1 and 0.4 mg/ml WRE relative to the control
(Table 2, p < 0.0001). In PBMC’s, the increased caspase
activity may be related to the decreased GSH levels at
24 h. A decrease in GSH levels may allow for an increase
in ROS levels which can activate apoptotic pathways.
Caspase-3/7 activity was increased in PBMC’s by 0.05–0.
4 mg/ml WRE compared to the control (Table 2, p < 0.
0001), suggesting an increased execution of apoptotic cell
death. In azoxymethane-induced colon cancer in mice,
W. somnifera has been shown to modulate TCA cycle
enzymes and the electron transport chain [41]. The
PBMC ATP levels were increased by 0.1, 0.4 mg/ml
WRE but decreased by 0.05, 0.2 mg/ml WRE compared
to the control (Table 2, p < 0.0001), which may be re-
lated to the modulation of the electron transport chain
by W. somnifera.
WRE pro-apoptotic effects in THP-1 cells treated for
24 h are shown in Table 3. At 24 h, THP-1 caspase-9 ac-
tivity was decreased by 0.2 mg/ml WRE but increased by 0.
05, 0.1, 0.4 mg/ml WRE compared to the control (Table 3,
Fig. 2 Cell viability of PBMC’s (a – 24 h, b – 72 h) and THP-1 (c – 24 h, d – 72 h) cells treated with WRE for 24 and 72 h (Values expressed as
mean ± SD, * p < 0.05,** p < 0.005, *** p < 0.0001 compared to the control)
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p < 0.0001). At 0.2 mg/ml WRE, the decreased caspase-9
activity may be related to the increased GSH levels. An in-
crease in GSH levels may decrease ROS levels thus mini-
mising mitochondrial depolarisation and the activation
of the intrinsic apoptotic pathway. In THP-1 cells, WRE
(0.05–0.4 mg/ml) decreased caspase-8 activity, whereas
increased caspase-3/7 activity and ATP levels relative to
the control (Table 3, p < 0.0001). Elevated caspase (-9,
-3/7) activities suggests the initiation of the mitochon-
drial apoptotic pathway.
The pro-apoptotic effect of WRE in PBMC’s treated for
72 h is shown in Table 4. At 72 h, PBMC caspase-8
activity was increased by 0.05–0.2 mg/ml WRE but de-
creased by 0.4 mg/ml WRE compared to the control
(Table 4, p < 0.0001). PBMC caspase-9 activity was in-
creased by 0.05–0.1 mg/ml WRE but decreased by 0.2–0.
4 mg/ml WRE relative to the control (Table 4, p < 0.
0001). In PBMC’s, caspase-3/7 activity was increased by
0.05, 0.1, 0.4 mg/ml WRE whereas it decreased by 0.
2 mg/ml WRE compared to the control (Table 4, p < 0.
0001). At 0.05–0.1 mg/ml WRE, the increased caspase-3/
7 activity is consistent with the significantly increased
caspase -8 and -9 activity. At 0.2 mg/ml WRE, caspase-8 ac-
tivity was minimally increased and caspase-9 activity
significantly decreased which lead to the decreased
caspase-3/7 activity. At 0.4 mg/ml WRE, although both cas-
pase -8 and -9 activities were decreased, caspase-3/7 activity
was increased. A previous study has demonstrated that one
activated executioner caspase can cleave and activate other
executioner caspases resulting in positive feedback loop of
caspase activation [42] which may account for the increased
caspase-3/7 activity at 0.4 mg/ml WRE. WRE (0.05–0.
4 mg/ml) decreased PBMC ATP levels relative to the
control (Table 4, p < 0.0001).
WRE pro-apoptotic effects in THP-1 cells treated for
72 h are shown in Table 5. At 72 h, THP-1 caspase (-8, -9,
-3/7) activity and ATP levels were increased by 0.1–0.
2 mg/ml WRE as compared to the control (Table 5, p < 0.
0001), suggesting an increase in THP-1 apoptotic cell
death. THP-1 caspase (-8, -9, -3/7) activity and ATP levels
were decreased by 0.05, 0.4 mg/ml WRE relative to the
control (Table 5, 72 h, p < 0.0001), suggesting a decrease
in THP-1 apoptosis.
Discussion
Cachexia patients experience excessive weight loss due
to increased lipolysis and proteolysis which have been
linked to elevated levels of pro-inflammatory cytokines,
Fig. 3 Concentration of TNF-α (a), IL-1β (b), IL-6 (c) and IL-10 (d) in LPS stimulated and WRE treated PBMC’s (Values expressed as mean ± SD, *p < 0.05,
*** p < 0.0001, compared to the control)
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oxidative stress and apoptosis [3, 5, 30]. Previously, the
powdered root of W. somnifera displayed immune modu-
latory properties [43] and WSF has been shown to in-
crease caspase-3 activity, subsequently inducing apoptosis
[38]. The objective of this study was thus to investigate
the modulation of cytokines, antioxidants and cell death
by WRE in PBMC’s and THP-1 cells.
Dhanani et al. (2017) showed that the root extract of
W. somnifera inhibited 50% of DPPH at a concentration
of 0.4 mg/ml [44]. Our results indicated that WRE has
oxidant scavenging potential ranging between 13 and
46% at 0.05–0.4 mg/ml. ROS plays an essential role in
tumour initiation, inflammation, protein degradation
and apoptosis. The antioxidant potential of WRE may de-
crease inflammatory cytokine levels as well as ROS in-
duced apoptosis.
At 24 h, the WST-1 results indicated that WRE de-
creased PBMC viability whilst increasing THP-1 viability.
However at 72 h, WRE increased PBMC viability whilst
conversely decreasing THP-1 viability. In contrast, the
growth of various cell lines (HT-29, HCT-15, SW620,
502,713, Colo-205, A549, HOP-62 and Hep-G2) were
dose dependently inhibited by WSF and 50% cell growth
inhibition was seen at 30 μg/ml WSF [38].
Table 1 Glutathione levels in LPS stimulated and WRE treated PBMC’s and THP-1 cells
Glutathione (μM)
WRE (mg/ml) 24 h Treatment 72 h Treatment
PBMC THP-1 PBMC THP-1
Control 1.613 ± 0.017 1.632 ± 0.004 4.799 ± 0.008 1.608 ± 0.004
0.05 1.442 ± 0.024 *** 1.267 ± 0.004 *** 5.232 ± 0.011 *** 1.548 ± 0.002 ***
0.1 1.617 ± 0.002 2.045 ± 0.002 *** 4.015 ± 0.001 *** 1.589 ± 0.004 ***
0.2 1.390 ± 0.001 *** 3.253 ± 0.017 *** 2.323 ± 0.005 *** 1.401 ± 0.006 ***
0.4 1.321 ± 0.006 *** 2.785 ± 0.005 *** 4.697 ± 0.003 *** 1.411 ± 0.005 ***
(Values expressed as mean ± SD, *** p < 0.0001, compared to the control)
Fig. 4 Concentration of TNF-α (a), IL-1β (b), IL-6 (c) and IL-10 (d) in LPS stimulated and WRE treated THP-1 cells (Values expressed as mean ± SD,
*p < 0.05, ***p < 0.0001 compared to the control)
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The pivotal role of inflammatory cytokines in malignan-
cies and cachexia has been extensively documented [3].
Dhuley (1997) previously reported that W. somnifera in-
hibits macrophage production of inflammatory cytokines
(IL-1, TNF-α) [45]. Our results showed that WRE de-
creased PBMC TNF-α, IL-10 and IL-6 levels, although it
increased IL-1β levels. In THP-1 cells, pro-inflammatory
cytokine (TNF-α, IL-1β, IL-6) levels were significantly de-
creased by WRE.
Pro-inflammatory cytokines, over a longstanding time
period, stimulate the production of genotoxic molecules
[nitric oxide (NO), ROS] and tumour progression by
promoting angiogenesis and metastasis [1, 2]. In
addition, pro-inflammatory cytokines activate NF-κB
which regulates the expression of genes involved in the
suppression of tumour apoptosis, stimulation of tumour
cell cycle progression and enhancement of inflammatory
mediators [1, 2]. NF-κB promotes tumour progression,
invasion, angiogenesis and metastasis [1, 2].
Previous literature has shown that IL-1 stimulates
growth and invasion of malignant cells [2]. Additionally,
IL-6 has been shown to target cell cycle progression and
anti-apoptotic genes leading to tumour proliferation and
anti-apoptotic potential [2]. The ability of WRE to in-
crease pro-inflammatory cytokines such as IL-1β in
PBMC’s may aid in cancerous cell elimination through
increased host anti-tumour activity. Conversely, in THP-
1 cells, the decrease in TNF-α, IL-6 and IL-1β levels by
WRE may prevent excessive activation of NF-κB, dimin-
ish cytokine induced tumour immunosuppressive activ-
ity and cancer progression.
With regard to cancer cachexia, IL-6 decreased LPL ac-
tivity in adipose tissue of mice [22] and IL-1 directly mod-
ulates lipid metabolism by suppressing LPL activity [23].
TNF-α decreased LPL activity in adipose tissue of human
(maintained in organ culture), rat, mouse, and guinea pigs
[21]. Additionally, TNF-α inhibits the production of LPL
and reduces the rate of LPL gene transcription in mouse
3 T3-L1 adipocytes, hence preventing the formation of
new lipid stores while stimulating HSL and increasing
lipolysis [3, 20, 46]. The potential of WRE to decrease pro-
inflammatory cytokine levels in PBMC’s and THP-1 cells
suggests a decrease in LPL inhibition and HSL stimula-
tion, thus maintaining lipogenesis and minimizing lipoly-
sis. IL-6 and TNF-α further contribute to cachexia by
stimulating muscle catabolism via the activation of prote-
asome pathways [24, 25, 47]. In cachexia, NF-κB activa-
tion induces ubiquitin–proteasome pathway activity and
suppresses MyoD expression [48], thereby increasing pro-
teolysis and reducing muscle replenishment [49]. By de-
creasing TNF-α and IL-6 levels in PBMC’s and THP-1
cells, WRE may prevent excessive activation of NF-κB and
proteasome pathways, ultimately decreasing proteolysis
associated with the cachectic syndrome. Taken together,
WRE may be able to decrease tissue wasting through the
down regulation of pro-inflammatory cytokine levels.
The immunosuppressive and anti-inflammatory cytokine,
IL-10, inhibits tumour development, tumour progression,
modulates apoptosis and suppresses angiogenesis during
tumour regression [1, 2]. Additionally, IL-10 inhibits NF-κB
activation and subsequently inhibits pro-inflammatory cyto-
kine production (TNF-α, and IL-6) [2]. In PBMC’s and
Table 2 Modulation of caspase (-8, -9, -3/7) activity and ATP levels in LPS stimulated and 24 h WRE treated PBMC’s
WRE (mg/ml) Caspase-8 (RLU × 10
5) Caspase-9 (RLU × 105) Caspase-3/7 (RLU × 105) ATP (RLU × 105)
Control 0.185 ± 0.006 0.366 ± 0.0003 7.756 ± 0.006 4.714 ± 0.004
0.05 0.155 ± 0.0002 *** 0.376 ± 0.001 *** 8.109 ± 0.094 ** 2.783 ± 0.017 ***
0.1 0.192 ± 0.00002 0.253 ± 0.0002 *** 11.504 ± 0.253 *** 5.208 ± 0.005 ***
0.2 0.246 ± 0.0003 *** 0.397 ± 0.0005 *** 8.961 ± 0.015 *** 3.741 ± 0.033 ***
0.4 4.814 ± 0.006 *** 0.351 ± 0.001 *** 17.095 ± 0.089 *** 6.965 ± 0.039 ***
(Values expressed as mean ± SD, ** p < 0.005, *** p < 0.0001 compared to the control)
Table 3 Modulation of caspase (-8, -9, -3/7) activity and ATP levels in LPS stimulated and 24 h WRE treated THP-1 cells
WRE (mg/ml) Caspase-8 (RLU × 10
5) Caspase-9 (RLU × 105) Caspase-3/7 (RLU × 105) ATP (RLU × 105)
Control 10.207 ± 0.011 1.040 ± 0.007 1.251 ± 0.016 2.636 ± 0.011
0.05 8.440 ± 0.039 *** 2.365 ± 0.005 *** 1.315 ± 0.005 *** 3.726 ± 0.005 ***
0.1 2.413 ± 0.005 *** 2.459 ± 0.002 *** 2.294 ± 0.006 *** 5.132 ± 0.014 ***
0.2 7.149 ± 0.027 *** 0.775 ± 0.002 *** 3.406 ± 0.006 *** 29.838 ± 0.186 ***
0.4 2.456 ± 0.033 *** 3.197 ± 0.0001 *** 9.428 ± 0.004 *** 10.282 ± 0.195 ***
(Values expressed as mean ± SD, *** p < 0.0001 compared to the control)
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THP-1 cells, the decreased IL-10 levels may be due to IL-
10 combating increased pro-inflammatory cytokines levels
(TNF-α, IL-6, IL-1β).
Antioxidants protect cells from increased oxidative stress
[50]. GSH is a potent antioxidant that effectively scavenges
ROS both directly and indirectly [50]. W. somnifera has
previously been shown to possess chemo-preventive activity
which may be a consequence of its antioxidant capacity
[39]. The 24 h results showed that WRE decreased GSH
levels in PBMC’s, whereas it increased GSH levels in THP-
1 cells. However, at 72 h, WRE decreased GSH levels in
both cell lines. Notably, GSH levels (72 h) were higher in
control PBMC’s (4.79 μM) compared to control THP-1
cells (1.61 μM), suggesting a higher oxidant defence in
PBMC’s.
The extrinsic (death receptors) and intrinsic (mito-
chondria) pathways are the two main apoptotic pathways
[29]. Activation of initiator caspases (-8, -9) leads to the
activation of executioner caspases (-3/7) resulting in ac-
tivation of cytoplasmic endonucleases [29]. In HL-60
cells, WSF treatment led to a loss of mitochondrial
membrane potential, translocation of Bax to mitochon-
dria, release of cytochrome c, Smac/DIABLO and apop-
tosis inducing factor, suggesting the activation of the
intrinsic apoptotic pathway [38]. Additionally, WSF
treated HL-60 cells showed an over-expression of TNF
receptor-1 and death receptor-4 with associated caspase-
8 activation, suggesting the activation of the extrinsic
apoptotic pathway [38]. Our 24 h results showed that
WRE increased PBMC caspase -8, -9 and -3/7 activities
at different concentrations, suggesting the activation of
extrinsic and intrinsic apoptotic pathways. In the same
time period, WRE increased THP-1 caspase -9 and -3/7
activities, suggesting initiation of apoptosis through the
intrinsic pathway. At 72 h, WRE (0.05–0.1 mg/ml) in-
creased caspase (-8, -9, -3/7) activities, suggesting an in-
creased initiation of PBMC apoptotic cell death.
However, 0.4 mg/ml WRE decreased initiator caspase (-8,
-9) activities, suggesting a decreased initiation of PBMC
apoptotic cell death. In THP-1 cells, 0.1–0.2 mg/ml WRE
(72 h) increased caspase (-8, -9, -3/7) activities, suggest-
ing initiation of apoptosis through the intrinsic and ex-
trinsic pathways. However, at 0.05 and 0.4 mg/ml WRE
(72 h), THP-1 caspase (-8, -9, -3/7) activities were de-
creased, suggesting a decrease in THP-1 apoptosis. Pre-
vious studies have indicated that W. somnifera may
activate the extrinsic and intrinsic apoptotic pathways
[38], therefore our results prove to be consistent with
other studies.
Increased caspase-3 activity, proteasome activity and
E3 ubiquitin-conjugating enzyme expression is associ-
ated with increased proteolysis [51]. Therefore the ability
of WRE (0.4 mg/ml, 72 h) to down regulate caspase ac-
tivity in PBMC’s and THP-1 cells may decrease proteoly-
sis and the progression of cancer cachexia.
A successful anti-cancer drug should kill or incapacitate
cancer cells without causing excessive damage to normal
cells [39]. The potential of WRE to regulate PBMC apop-
tosis while increasing cancerous THP-1 cell apoptosis may
be beneficial to cancer patients by preventing excessive
cancerous cell growth while minimally effecting healthy
PBMC’s.
Table 5 Modulation of caspase (-8, -9, -3/7) activity and ATP levels in LPS-stimulated and 72 h WRE-treated THP-1 cells
WRE (mg/ml) Caspase-8 (RLU × 10
5) Caspase-9 (RLU × 105) Caspase-3/7 (RLU × 105) ATP (RLU × 105)
Control 0.991 ± 0.0001 5.738 ± 0.002 7.463 ± 0.012 4.332 ± 0.002
0.05 0.978 ± 0.0001 *** 5.562 ± 0.009 *** 6.919 ± 0.003 *** 4.133 ± 0.005 ***
0.1 1.216 ± 0.001 *** 7.045 ± 0.005 *** 8.211 ± 0.002 *** 4.889 ± 0.005 ***
0.2 1.095 ± 0.001 *** 6.091 ± 0.001 *** 7.532 ± 0.006 *** 4.576 ± 0.004 ***
0.4 0.952 ± 0.0003 *** 5.639 ± 0.003 *** 6.626 ± 0.007 *** 4.039 ± 0.0003 ***
(Values expressed as mean ± SD, *** p < 0.0001 compared to the control)
Table 4 Modulation of caspase (-8, -9, -3/7) activity and ATP levels in LPS stimulated and 72 h WRE treated PBMC’s
WRE (mg/ml) Caspase-8 (RLU × 10
5) Caspase-9 (RLU × 105) Caspase-3/7 (RLU × 105) ATP (RLU × 105)
Control 42.651 ± 0.039 115.041 ± 3.848 155.556 ± 0.387 20.574 ± 0.316
0.05 53.840 ± 0.026 *** 143.861 ± 3.929 *** 196.471 ± 0.338 *** 10.223 ± 0.046 ***
0.1 52.109 ± 0.009 *** 129.033 ± 0.289 *** 192.695 ± 0.233 *** 12.506 ± 0.373 ***
0.2 42.751 ± 0.039 ** 105.494 ± 4.247 ** 154.203 ± 0.224 *** 13.210 ± 0.043 ***
0.4 29.656 ± 0.007 *** 92.718 ± 0.021 *** 165.139 ± 0.096 *** 13.361 ± 0.279 ***
(Values expressed as mean ± SD,** p < 0.005, *** p < 0.0001 compared to the control)
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Conclusion
The cachectic syndrome decreases the quality of life of
patients, the responsiveness to chemotherapy and leads
to 20–25% of cancer deaths [3]. Our results show that
WRE increased oxidant scavenging activity, modulated
GSH and pro-inflammatory cytokine levels and regulated
caspase activity in normal PBMC’s and THP-1 cells. The
discovery of a medicinal plant capable of decreasing the
levels of pro-inflammatory cytokines may decrease tissue
wasting. In this study, the root extract of W. somnifera has
shown promising results in modulating the production of
cytokines associated with cancer cachexia. The ability of
WRE to decrease pro-inflammatory cytokine levels and in-
crease cancerous cell death may decrease the development
and progression of cancer and cachexia. WRE may there-
fore be effective in cancer cachexia.
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